Tag Archives: NASDAQ:PRGS

Analysts’ Perspective: Surgery Partners (SGRY), Progress Software (PRGS), Air Transport Services Group (ATSG)

Investment Analysts at Stifel upgraded Surgery Partners, Inc. (NASDAQ:SGRY) shares from Sell to Hold rating with a price target of $15.

Surgery Partners, Inc., through its subsidiaries, operates surgical facilities in the United States.

*

Brokerage Firm The Benchmark Company upgraded Progress Software Corporation (NASDAQ:PRGS) shares from Sell to Hold rating.

Progress Software Corporation provides software solutions for various industries worldwide.

*

Air Transport Services Group, Inc. (NASDAQ:ATSG) shares were upgraded by analysts at Stifel from Hold to Buy rating while increasing their price target from $23 to $26.

Air Transport Services Group, Inc., through its subsidiaries, operates in the airfreight and logistics industry.

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://www.crwe.info/disclaimer/

Analysts’ View: U.S. Steel (X), Progress Software (PRGS), EXACT Sciences (EXAS)

Brokerage Firm Citigroup upgraded United States Steel Corp. (NYSE:X) shares from Neutral to Buy rating.

United States Steel Corp. engages in the manufacturing and selling of steel products.

*

Investment Analysts at Sidoti upgraded Progress Software Corp. (NASDAQ:PRGS) shares from Neutral to Buy rating.

Progress Software Corp. engages in the provision of a platform, which develops and deploy mission-critical business applications.

*

EXACT Sciences Corp. (NASDAQ:EXAS) shares were upgraded by analysts at BTIG Research from Neutral to Buy rating.

EXACT Sciences Corp. is a molecular diagnostics company, which is focused on the early detection and prevention of colorectal cancer.

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://www.crwe.info/disclaimer/